Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: A systematic review with meta-analyses and forecasting study.
Nordic countries
age-related macular degeneration
geographic atrophy
meta-analysis
pegcetacoplan
systematic review
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
25
05
2023
accepted:
30
08
2023
medline:
8
11
2023
pubmed:
8
9
2023
entrez:
8
9
2023
Statut:
ppublish
Résumé
We systematically reviewed the literature on the prevalence of geographic atrophy (GA) in Nordic populations, conducted meta-analyses on age-stratified estimates, and calculated current and future number of patients and those potentially eligible for intravitreal complement inhibitor treatment. We followed the PRISMA guidelines, and our protocol was registered in PROSPERO. Ten databases were searched on 22 April 2023 for population-based studies of GA prevalence. Based on clinical descriptive analyses of GA and eligibility criteria of the phase III studies for intravitreal pegcetacoplan (complement C3 and C3b inhibitor), we were able to calculate the proportion of patients with GA potentially eligible for therapy. Finally, we extracted population data for Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) from Eurostat, applied prevalence statistics to the extracted census and forecasting data to estimate the number of patients with GA, and then applied the proportion eligible for intravitreal pegcetacoplan therapy. We identified six studies with a total of 10 159 individuals. Prevalence of GA was estimated to 0.4% (95% confidence intervals [CI]: 0.2%-0.8%), 1.5% (95% CI: 0.7%-2.6%), and 7.6% (95% CI: 4.6%-11.3%) for individuals aged 60-69, 70-79, and 80+ years, respectively. In Nordic countries, we estimate a total of 166 307 individuals with GA in 2023, increasing to 277 893 in 2050. Of these, 90 803 individuals in 2023, increasing to 151 730 in 2050, are potentially eligible for intravitreal complement inhibitor treatment. Considering these large numbers, our study highlights the importance of this topic in the coming years and its potential to significantly impact our clinical practice, organization, and staffing.
Substances chimiques
Complement Inactivating Agents
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
857-868Informations de copyright
© 2023 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Ahluwalia, A., Shen, L.L., Bao, Y., Sun, M., Young, B.K., Park, M.M. et al. (2023) The influence of the topographic location of geographic atrophy on vision-related quality of life in nonexudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 261, 699-708.
Barendregt, J.J., Doi, S.A., Lee, Y.Y., Norman, R.E. & Vos, T. (2013) Meta-analysis of prevalence. Journal of Epidemiology and Community Health, 67, 974-978.
Bjerager, J., Schneider, M., Potapenko, I., van Dijk, E.H.C., Faber, C., Grauslund, J. et al. (2023) Diagnostic accuracy of the Amsler grid test for detecting neovascular age-related macular degeneration: a systematic review and meta-analysis. JAMA Ophthalmology, 141, 315-323.
Björnsson, O.M., Syrdalen, P., Bird, A.C., Peto, T. & Kinge, B. (2006) The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: the Oslo macular study. Acta Ophthalmologica Scandinavica, 84, 636-641.
Brynskov, T., Munch, I.C., Larsen, T.M., Erngaard, L. & Sørensen, T.L. (2020) Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Acta Ophthalmologica, 98, 132-138.
Buch, H., Vinding, T., la Cour, M., Jensen, G.B., Prause, J.U. & Nielsen, N.V. (2005) Risk factors for age-related maculopathy in a 14-year follow-up study: the Copenhagen City eye study. Acta Ophthalmologica Scandinavica, 83, 409-418.
Clevenger, L. & Rachitskaya, A. (2023) Identifying geographic atrophy. Current Opinion in Ophthalmology, 34, 195-202.
ClinicalTrials.gov NCT03525600. (2022) Available from: https://clinicaltrials.gov/ct2/show/NCT03525600 [Accessed 13th May, 2023].
ClinicalTrials.gov NCT03525613. (2022) Available from: https://clinicaltrials.gov/ct2/show/NCT03525613 [Accessed 13th May, 2023].
Cochrane. (2022) Cochrane handbook for systematic reviews of interventions version 6.3. Available from: http://www.training.cochrane.org/handbook [Accessed 13th May, 2023].
Colijn, J.M., Buitendijk, G.H.S., Prokofyeva, E., Alves, D., Cachulo, M.L., Khawaja, A.P. et al. (2017) Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology, 124, 1753-1763.
Crincoli, E., De Rosa, I., Miere, A., Colantuono, D., Mehanna, C.J. & Souied, E.H. (2022) Comparison of multimodal imaging for the characterization of geographic atrophy. Translational Vision Science & Technology, 11, 21.
de Breuk, A., Lechanteur, Y.T.E., Heesterbeek, T.J., Fauser, S., Klaver, C.C.W., Hoyng, C.B. et al. (2021) Genetic risk in families with age-related macular degeneration. Ophthalmology Science, 1, 100087.
Desai, D. & Dugel, P.U. (2022) Complement cascade inhibition in geographic atrophy: a review. Eye (London, England), 36, 294-302.
England, K. & Azzopardi-Muscat, N. (2017) Demographic trends and public health in Europe. European Journal of Public Health, 27, 9-13.
Erke, M.G., Bertelsen, G., Peto, T., Sjølie, A.K., Lindekleiv, H. & Njølstad, I. (2012) Prevalence of age-related macular degeneration in elderly Caucasians: the Tromsø eye study. Ophthalmology, 119, 1737-1743.
Eurostat. (2023) Available from: https://ec.europa.eu/eurostat [Accessed 13th May, 2023].
EyeWire. (2023) Available from: https://eyewire.news/news/fda-approves-apellis-syfovre-pegcetacoplan-first-and-only-treatment-for-geographic-atrophy [Accessed 13th May, 2023].
Feng, C., Krogh Nielsen, M., Sørensen, T.L. & Subhi, Y. (2020) Systemic levels of C-reactive protein in patients with age-related macular degeneration: a systematic review with meta-analyses. Mechanisms of Ageing and Development, 191, 111353.
Ferløv Baselius, N.J., Brynskov, T., Falk, M.K., Sørensen, T.L. & Subhi, Y. (2021) Driving vision in patients with neovascular AMD in anti-VEGF treatment. Acta Ophthalmologica, 99, e1360-e1365.
Flaxman, S.R., Bourne, R.R.A., Resnikoff, S., Ackland, P., Braithwaite, T., Cicinelli, M.V. et al. (2017) Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. The Lancet Global Health, 5, e1221-e1234.
Fleckenstein, M., Keenan, T.D.L., Guymer, R.H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C.C. et al. (2021) Age-related macular degeneration. Nature Reviews. Disease Primers, 7, 31.
Forshaw, T.R.J., Minör, Å.S., Subhi, Y. & Sørensen, T.L. (2019) Peripheral retinal lesions in eyes with age-related macular degeneration using ultra-Widefield imaging: a systematic review with meta-analyses. Ophthalmology Retina, 3, 734-743.
Goldberg, R., Heier, J.S., Wykoff, C.C., Staurenghi, G., Singh, R.P., Steinle, N. et al. (2022) Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. Investigative Ophthalmology & Visual Science, 63, 1500.
Haji, H., Gianniou, C., Brynskov, T., Sørensen, T.L., Olsen, R. & Krogh Nielsen, M. (2023) Association between structural and functional treatment outcomes in neovascular age-related macular degeneration. Acta Ophthalmologica, 101, 177-184.
Heloterä, H. & Kaarniranta, K. (2022) A linkage between angiogenesis and inflammation in neovascular age-related macular degeneration. Cell, 11, 3453.
Holm, D.L., Nielsen, M.K., Højsted, B.B. & Sørensen, T.L. (2023) Vision-related quality of life is selectively affected by comorbidities in patients with geographic atrophy. BMC Ophthalmology, 23, 153.
Holtz, J.K., Thinggaard, B.S., Grauslund, J. & Subhi, Y. (2023) Association between oral metformin use and the risk of age-related macular degeneration: a systematic review with meta-analysis. Acta Ophthalmologica, 101, 595-605.
Holz, F.G., Bindewald-Wittich, A., Fleckenstein, M., Dreyhaupt, J., Scholl, H.P., Schmitz-Valckenberg, S. et al. (2007) Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. American Journal of Ophthalmology, 143, 463-472.
Jonasson, F., Arnarsson, A., Eiríksdottir, G., Harris, T.B., Launer, L.J., Meuer, S.M. et al. (2011) Prevalence of age-related macular degeneration in old persons: age, gene/environment susceptibility Reykjavik study. Ophthalmology, 118, 825-830.
Jonasson, F., Arnarsson, A., Sasaki, H., Peto, T., Sasaki, K. & Bird, A.C. (2003) The prevalence of age-related maculopathy in iceland: Reykjavik eye study. Archives of Ophthalmology, 121, 379-385.
Kaarniranta, K., Blasiak, J., Liton, P., Boulton, M., Klionsky, D.J. & Sinha, D. (2023) Autophagy in age-related macular degeneration. Autophagy, 19, 388-400.
Kim, H.S., Lee, S. & Kim, J.H. (2018) Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. Journal of Korean Medical Science, 33, e213.
Krogh Nielsen, M., Subhi, Y., Molbech, C.R., Falk, M.K., Nissen, M.H. & Sørensen, T.L. (2020) Chemokine profile and the alterations in CCR5-CCL5 Axis in geographic atrophy secondary to age-related macular degeneration. Investigative Ophthalmology & Visual Science, 61, 28.
Krogh Nielsen, M., Subhi, Y., Molbech, C.R., Falk, M.K., Singh, A., Nissen, M.H. et al. (2019) Patients with a fast progression profile in geographic atrophy have increased CD200 expression on circulating monocytes. Clinical & Experimental Ophthalmology, 47, 69-78.
Künzel, S.H., Lindner, M., Sassen, J., Möller, P.T., Goerdt, L., Schmid, M. et al. (2021) Association of reading performance in geographic atrophy secondary to age-related macular degeneration with visual function and structural biomarkers. JAMA Ophthalmology, 139, 1191-1199.
Laatikainen, L. & Hirvelä, H. (1995) Prevalence and visual consequences of macular changes in a population aged 70 years and older. Acta Ophthalmologica Scandinavica, 73, 105-110.
Lindekleiv, H. & Erke, M.G. (2013) Projected prevalence of age-related macular degeneration in Scandinavia 2012-2040. Acta Ophthalmologica, 91, 307-311.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. & PRISMA Group. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, b2535.
Nahavandipour, A., Krogh Nielsen, M., Sørensen, T.L. & Subhi, Y. (2020) Systemic levels of interleukin-6 in patients with age-related macular degeneration: a systematic review and meta-analysis. Acta Ophthalmologica, 98, 434-444.
Nielsen, M.K., Subhi, Y., Molbech, C.R., Grønskov, K. & Sørensen, T.L. (2020) Distribution of risk alleles in patients with age-related macular degeneration. Danish Medical Journal, 67, A05190295.
Petri, A.S., Boysen, K., Cehofski, L.J., van Dijk, E.H.C., Dysli, C., Fuchs, J. et al. (2020) Intravitreal injections with vascular endothelial growth factor inhibitors: a practical approach. Ophthalmology and Therapy, 9, 191-203.
Rozing, M.P., Durhuus, J.A., Krogh Nielsen, M., Subhi, Y., Kirkwood, T.B., Westendorp, R.G. et al. (2020) Age-related macular degeneration: a two-level model hypothesis. Progress in Retinal and Eye Research, 76, 100825.
Sedeh, F.B., Scott, D.A.R., Subhi, Y. & Sørensen, T.L. (2017) Prevalence of neovascular age-related macular degeneration and geographic atrophy in Denmark. Danish Medical Journal, 64, A5422.
Steinle, N.C., Pearce, I., Monés, J., Metlapally, R., Saroj, N., Hamdani, M. et al. (2021) Impact of baseline characteristics on geographic atrophy progression in the FILLY trial evaluating the complement C3 inhibitor pegcetacoplan. American Journal of Ophthalmology, 227, 116-124.
Subhi, Y., Krogh Nielsen, M., Molbech, C.R., Oishi, A., Singh, A., Nissen, M.H. et al. (2019) Plasma markers of chronic low-grade inflammation in polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Acta Ophthalmologica, 97, 99-106.
Subhi, Y., Nielsen, M.K., Molbech, C.R., Liisborg, C., Søndergaard, H.B., Sellebjerg, F. et al. (2019) The transcriptome of peripheral blood mononuclear cells in patients with clinical subtypes of late age-related macular degeneration. Immunity & Ageing, 16, 20.
Subhi, Y. & Sørensen, T.L. (2017) Neovascular age-related macular degeneration in the very old (≥90 years): epidemiology, adherence to treatment, and comparison of efficacy. Journal of Ophthalmology, 2017, 7194927.
van Spall, H.G., Toren, A., Kiss, A. & Fowler, R.A. (2007) Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA, 297, 1233-1240.
Zeng, X., Zhang, Y., Kwong, J.S., Zhang, C., Li, S., Sun, F. et al. (2015) The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. Journal of Evidence-Based Medicine, 8, 2-10.